Bryden Considine, DO, and Daniel P. Petrylak, MD
Here, we review the current use and future direction of novel therapeutic targets in the treatment of castration-resistant prostate cancer.
Alexandria M. Hertz, MD, Timothy C. Brand, MD, and Matthew M. Banti, MD
A 39-year-old man is diagnosed with pure post-pubertal teratoma of the testis. What are the best steps of management?
One FDA-Approved test analyzes 324 cancer-related genes
FoundationOne®CDx analyzes all recommend genomic biomarkers for solid tumors, including companion diagnostic indications with direct paths to therapy. This one test can help guide therapy selection and clinical trial options for more patients.
Read more
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: UBM Medica, a divsion of UBM Americas
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
Bryden Considine, DO, and Daniel P. Petrylak, MD
Alexandria M. Hertz, MD, Timothy C. Brand, MD, and Matthew M. Banti, MD
